Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 17 (1), 90

Abnormalities in Ileal Stem, Neurogenin 3, and Enteroendocrine Cells in Patients With Irritable Bowel Syndrome

Affiliations

Abnormalities in Ileal Stem, Neurogenin 3, and Enteroendocrine Cells in Patients With Irritable Bowel Syndrome

Magdy El-Salhy et al. BMC Gastroenterol.

Abstract

Background: This study examined whether the densities of stem- and enteroendocrine cell progenitors are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormalities in ileal enteroendocrine cells are correlated with abnormalities in stem cells and enteroendocrine cell progenitors.

Methods: One hundred and one IBS patients covering all IBS subtypes were recruited, and 39 non-IBS subjects were included as a control group. The patients and controls underwent standard colonoscopies, during which biopsy specimens were obtained from the ileum. The biopsy specimens were stained with hematoxylin-eosin and immunostained for Musashi-1 (Msi-1), neurogenin 3 (NEUROG3), chromogranin A (CgA), serotonin, peptide YY (PYY), oxyntomodulin (enteroglucagon), pancreatic polypeptide, and somatostatin. The immunoreactive cells were quantified by computerized image analysis.

Results: The densities of Msi-1, NEUROG3, CgA, and serotonin cells were reduced in all IBS patients and in patients with diarrhea-predominant IBS (IBS-D), mixed-diarrhea-and-constipation IBS (IBS-M), and constipation-predominant (IBS-C) relative to the control subjects. While the PYY cell density was increased in IBS-C relative to controls, it did not differ between control subjects and IBS-D and IBS-M patients. The densities of Msi-1 and NEUROG3 cells were strongly correlated with that of CgA cells.

Conclusions: The abnormalities in the ileal enteroendocrine cells appear to be caused by two mechanisms: (1) decreases in the clonogenic activity of the stem cells and in the endocrine-cell progenitors differentiating into enteroendocrine cells, and (2) switching on the expression of PYY and switching off the expression of certain other hormones in other types of the enteroendocrine cells.

Keywords: Enteroendocrine cells; IBS; Ileum; Immunohistochemistry; Mushasi-1; Neurogenin 3; PYY; Serotonin.

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the Regional Committee for Medical and Health Research Ethics West, Bergen, Norway. All subjects gave both oral and written consents to participate.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Densities of Msi-1, NEUROG3, CgA, serotonin, and PYY cells in the ileum of control subjects and IBS-total, IBS-D, IBS-M, and IBS-C patients. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. controls (Dunn’s multiple-comparisons test)
Fig. 2
Fig. 2
Ileal Msi-1 cells in a control subject (a) and an IBS patient (b)
Fig. 3
Fig. 3
Ileal NEUROG3 cells in a control subject (a) and an IBS patient (b)
Fig. 4
Fig. 4
Ileal CgA cells in a control subject (a) and a patient with IBS (b)
Fig. 5
Fig. 5
Ileal serotonin cells in a control subject (a) and a patient with IBS (b)
Fig. 6
Fig. 6
Ileal PYY cells in a control subject (a) and a patient with IBS-C (b)
Fig. 7
Fig. 7
Correlations between the density of CgA cells and the densities of Msi-1 and NEUROG3 cells (Spearman nonparametric test)

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Thompson WG: A world view of IBS In: Irritable bowel syndrome: diagnosis and treatment. edn. Edited by Camilleri M, Spiller RC. Philadelphia and London: Saunders; 2002;17–26.
    1. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–1580. doi: 10.1007/BF01303162. - DOI - PubMed
    1. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable bowel syndrome: diagnosis, pathogenesis and treatment options. New York: Nova Science Publishers, Inc.; 2012.
    1. Ford AC, Vandvik PO. Irritable bowel syndrome. Clin Evid (Online). 2012;2012 - PMC - PubMed
    1. Quigley EM, Locke GR, Mueller-Lissner S, Paulo LG, Tytgat GN, Helfrich I, Schaefer E. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther. 2006;24:411–419. doi: 10.1111/j.1365-2036.2006.02989.x. - DOI - PubMed

MeSH terms

Feedback